Skip to content
Peptide (Research Chemical)Reviewed July 2026 · v1.0

MOTS-c

Mitochondrial-derived Peptide (research chemical)

Preclinical evidence is genuinely interesting, and MOTS-c rises with exercise in humans, but no human administration trial of native MOTS-c exists — so therapeutic benefit is ungraded and safety is unknown.

How confident is BioSignal?

Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.

Limited evidence

Preclinical evidence is genuinely interesting, and MOTS-c rises with exercise in humans, but no human administration trial of native MOTS-c exists — so therapeutic benefit is ungraded and safety is unknown.

Early or sparse human evidence; conclusions remain uncertain.

Human Evidence

Limited evidence

No trial of native MOTS-c administration; human data are observational (MOTS-c rises with exercise).

Mechanistic Plausibility

Moderate confidence

AMPK activation, metabolic homeostasis, and muscle/healthspan effects in mice.

Research Activity

Moderate

Active preclinical field; an analog reached early-phase trials then was discontinued.

Safety Profile

Caution

No human administration safety data for native MOTS-c; unregulated product.

Consensus

Limited evidence

Not approved; no clinical guideline status.

Where the evidence stands today

How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.

4/9

steps proven in humans

Evidence-poor

5 steps not demonstrated: Human safety data · Small human outcome trials · Large human RCTs · Clinical outcomes · Guideline / regulatory support

  1. Guideline / regulatory support

    Not shown

    Not approved.

  2. Clinical outcomes

    Not shown

    None.

  3. Large human RCTs

    Not shown

    None.

  4. Small human outcome trials

    Not shown

    None for native MOTS-c (an analog's early trials were discontinued).

  5. Human safety data

    Not shown

    No administration of native MOTS-c to humans.

  6. Human biomarker / pharmacology

    Proven

    Observational: endogenous MOTS-c rises with exercise.

  7. Animal

    Proven

    Mouse metabolic/physical-capacity effects.

  8. Cell / in vitro

    Proven

    Cell studies.

  9. Mechanistic plausibility

    Proven

    AMPK activation; mitochondrial metabolism.

The bottom line

What we know, what we think, what we don't know — and what would change our mind.

Mouse efficacy; human correlation

In mice and cells, MOTS-c activates AMPK, improves metabolic homeostasis, reduces diet-induced obesity/insulin resistance, and improves physical capacity with aging; in humans, MOTS-c rises with exercise (observational).

Rises with exercise ≠ mimics exercise

It is a compelling research target for metabolism and aging — but 'rises with exercise' is not the same as 'taking it reproduces exercise.'

Everything about administration

Whether administering MOTS-c benefits humans at all, safe dose, long-term safety, and product quality are unknown.

Preclinical + a discontinued analog

Preclinical research continues; a synthetic MOTS-c analog (not native MOTS-c) entered early-phase trials that were discontinued.

What would change the picture

A human administration trial of native MOTS-c would allow the first graded efficacy claim.

The biggest myth

Taking MOTS-c improves metabolism / mimics exercise in people.

Not establishedLimited evidence

No human administration trial of native MOTS-c exists; effects are demonstrated in mice, not humans.

Ask BioSignal

Still have a question about mots-c?

Answers are retrieved from this record and the rest of the knowledge graph — never generated.

Ask about MOTS-c

Why people take mots-c

Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.

People search MOTS-c for metabolic health, 'exercise-mimetic' effects, and longevity/mitochondrial support. Interest is not evidence: the efficacy data are in mice, the human data are observational (it rises with exercise), and there is no human administration trial — the proven way to raise your own MOTS-c is to exercise.

If you're here because…

Jump straight to the part of the evidence that answers your question.

Approval, safety and regulatory

What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.

Regulatory status

Not Approved

Availability

Unapproved research chemical

Sport (WADA)

Requires confirmation

Known safety profile

Unknown in humans for administered native MOTS-c (no trials); the analog's early-phase safety data pertain to a different molecule.

Common issues

  • Not characterized in humans

Use caution if

  • Everyone (unstudied)
  • Cancer history
  • Pregnancy
  • Metabolic disease

Long-term unknowns

All long-term safety.

Limits of this evidence

Efficacy data are preclinical; human data are observational; no administration trial of native MOTS-c.

Full regulatory and sport detail
Regulatory approval
None.
Approved indication
None.
Investigational
Native MOTS-c not in trials; a synthetic analog (distinct molecule) reached early-phase trials that were discontinued — confirm details against a trial registry before publication.
Research chemical
Yes — sold as a research chemical.
Compounding
Not applicable.
Sport (WADA)
Status not clearly established — requires confirmation at publication.
Publication note
Re-confirm regulatory and anti-doping status against primary sources at publication.

Demand, separated from evidence

Every claim people make about this, counted against what the evidence actually showed.

BioSignal evaluated 4 popular claims about mots-c.

Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.

Supported by evidence
1
Not established
3

Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.

Supported by evidence

  • MOTS-c rises with exercise in humans.

Not established

  • Taking MOTS-c improves metabolism / mimics exercise in people.
  • MOTS-c is a proven longevity/exercise-mimetic therapy.
  • MOTS-c is an available/approved therapy.

The evidence review

Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.

What people claim

Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.

MOTS-c rises with exercise in humans.SupportedLimited evidence

A small human study found exercise induces endogenous MOTS-c in muscle and blood (observational).

MOTS-c is a proven longevity/exercise-mimetic therapy.Not establishedLimited evidence

Preclinical only; no human efficacy data; an analog's early trials were discontinued.

MOTS-c is an available/approved therapy.Not establishedModerate confidence

Not approved; native MOTS-c has never been administered in a human trial; sold as a research chemical.

Doses used in human studies

What was actually given to participants in the research. These are descriptions of studies, not recommendations.

— (native MOTS-c)

Intervention
Administered MOTS-c
Dose
None
Duration
Outcome
Notes
No human administration trial of native MOTS-c exists.

Investigational (analog)

Intervention
MOTS-c analog (distinct molecule)
Dose
early-phase
Duration
Outcome
early-phase endpoints
Notes
Program discontinued; not native MOTS-c; details to confirm against trial registries.

Where scientists agree — and don’t

Agreed

  • MOTS-c has real mitochondrial/metabolic biology in preclinical models and is exercise-induced in humans

Debated

  • Whether exogenous administration would help humans
  • Translation from mouse to human

Unknown

  • All human administration efficacy, dose, and safety questions

What remains unknown

  • Is there any human benefit from administering native MOTS-c?
  • What is a safe human dose and the long-term safety?
  • What is the product identity/purity in unregulated supply?

Questions people actually ask

Does MOTS-c work like exercise?

In mice, MOTS-c improves metabolism and physical capacity. In humans, it rises with exercise — but no one has tested giving native MOTS-c to people, so there is no human evidence that taking it reproduces exercise's benefits.

Can I take MOTS-c?

It is unapproved and experimental. Products sold online are unregulated research chemicals with no human administration trials and unknown safety.

Practical takeaways

  • MOTS-c is a legitimately interesting research peptide — with strong mouse, not human, efficacy data.
  • It rises with exercise in humans, but that does not mean taking it reproduces exercise.
  • There are no human trials of administering native MOTS-c; benefit and safety are unknown.
  • An analog reached early trials and was discontinued — not evidence of a working therapy.
  • It is unapproved and experimental; the proven way to raise your own MOTS-c is to exercise.

How it works

The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.

How we found out

  1. 2015 — Lee (Cell Metab)

    Discovery; MOTS-c improves metabolic homeostasis in mice.

  2. 2021 — Reynolds (Nat Commun)

    Exercise induces MOTS-c in humans (observational); exogenous MOTS-c improves physical capacity in mice.

  3. ~2021–2023 — analog (distinct molecule)

    Early-phase human trials discontinued; no approval.

References

Verified sources. BioSignal does not print a citation it has not checked.

  1. 01

    The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

    Cell Metab 21(3):443-454 · 2015

  2. 02

    MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

    Nat Commun 12(1):470 · 2021

Version history

  • 1.0

    Initial review-hardened record (Experimental; Insufficient/Caution). Review cadence: Annual.